pentobarbital will decrease the level or impact of cilostazol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital decreases levels of elvitegravir/cobicistat/emtricitabine/tenofovir DF by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. May lead to loss of virologic reaction and attainable resistance.
pentobarbital will minimize the extent or outcome of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
pentobarbital will decrease the extent or influence of levoketoconazole by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unknown.
Contraindicated (1)pentobarbital will lower the extent or result of cobimetinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Prevent coadministration. Strong or average CYP3A inducers may perhaps decrease cobimetinib systemic exposure by >eighty% and decrease its efficacy.
pentobarbital will lessen the extent or result of quinine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unfamiliar.
pentobarbital will reduce the level or effect of midostaurin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Solid CYP3A4 inducers might minimize midostaurin concentrations resulting in decreased efficacy.
pentobarbital decreases consequences of hemin by pharmacodynamic antagonism. Use Warning/Observe. Drugs that improve delta-aminolevulinic acid synthetase could reduce hemin impact.
pentobarbital will reduce the level or impact of etravirine by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Keep track of.
pentobarbital will reduce the extent or influence of vinorelbine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Mysterious.
pentobarbital will reduce the extent or result of triamcinolone acetonide injectable suspension by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
pentobarbital will lessen the level or result of fedratinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Outcome of coadministering a solid CYP3A4 inducer with fedratinib has not been analyzed.
With therapeutic doses click here of TCAs, barbiturates increase metabolism and reduce blood concentrations of TCAs.
Keep an eye on Closely (2)pentobarbital will decrease the level or result of buprenorphine, very long-performing injection by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Check Carefully. Clients who transfer to buprenorphine long-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inducers needs to be monitored to guarantee buprenorphine plasma concentrations are sufficient.